Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump’s drug-pricing plans, including TrumpRx.

WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies’ earnings reports and analyst calls to find out what’s going on under the hood of the American economy.

Sign up for the WSJ's free Markets A.M. newsletter.

Further Reading:

Novo Nordisk Sweetens Offer for Metsera - WSJ

Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug Deal

Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk

The Day Pharma’s Weight-Loss Gold Rush Intensified

Pfizer Profit Falls Amid Lower Covid-19 Drug Demand

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera

Novo Nordisk to Shake Up Board After Obesity-Market Challenges

Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings

AbbVie Lifts Profit Outlook as Sales Rise

Bristol Myers Squibb Profit Soars, Raises Revenue Guidance

Merck Profit Rises on Strong Keytruda Demand

GSK Lifts Guidance After Specialty Medicines Boost Sales

Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains

Learn more about your ad choices. Visit megaphone.fm/adchoices